Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VEGF-C gene therapy - Herantis Pharma

Next Previous
Drug Profile

VEGF-C gene therapy - Herantis Pharma

Alternative Names: Ad-VEGF-C - Herantis Pharma; Lymfactin; Vascular endothelial growth factor gene therapy - Herantis Pharma

Latest Information Update: 05 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Helsinki
  • Developer Herantis Pharma
  • Class Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor C expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Lymphoedema

Highest Development Phases

  • Phase II Lymphoedema
  • Research Haematological disorders

Most Recent Events

  • 24 Apr 2023 Herantis Pharma terminates a phase I trial in Lymphoedema in Finland (Parenteral), due to lack of efficacy (NCT02994771)
  • 22 Mar 2021 Early research in Haematological disorders (lymphatic disorders) in Finland (Parenteral) (Herantis Pharma pipeline, March 2021)
  • 16 Dec 2019 Herantis Pharma completes enrolment in the phase II AdeLE trial for Lymphoedema in Sweden and Finland (NCT03658967)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top